Switzerland’s Spiez Laboratory at the heart of WHO’s BioHub system

 

The Spiez Laboratory will be the first facility to be part of the WHO’s BioHub system, an infrastructure that will facilitate the timely sharing of viruses and other pathogens between laboratories and partners worldwide.

 
Following a Memorandum of Understanding for the launch of the BioHub system between the World Health Organization (WHO) and the Swiss Confederation, the Spiez Laboratory was selected to become the first facility to serve the project.
 
Based in Spiez in the canton of Bern, this facility will serve as a center for the safe collection, sequencing, storage and preparation of biological materials for distribution to other laboratories, to serve as a basis for risk assessments and to support global preparedness against these pathogens.
 
“It is essential to maintain a close international collaboration to ensure the timely sharing of epidemiological and clinical data as well as biological materials. Switzerland supports the first phase of the WHO’s BioHub initiative by providing the necessary infrastructure of a Swiss biosafety laboratory in Spiez”, explains Federal Councillor Alain Berset.
 
A timely sharing of information to help the global scientific community.
 
Currently, most exchanges of pathogens are done on a bilateral basis between countries and on an ad hoc basis, which can be time consuming and puts some countries at a disadvantage.
 
The BioHub initiative will allow Member States to share biological materials with and through the BioHub system under pre-agreed conditions, including biosafety and biosecurity and any other applicable regulations.
 
This approach will ensure that response activities are carried out in a timely and predictable manner, including assisting the global scientific community in developing response tools such as diagnostics, treatments and vaccines.
 
The WHO is currently conducting a pilot phase using Sars-Cov-2 and its variants to test the feasibility and operational modalities of sharing these materials through the BioHub system facilities. Once the results of the trial period are known, the BioHub system will expand beyond Sars-Cov-2 and its variants to include other pathogens.

HubsGoGlobal is a platform under the PharmaBoardroom brand that focuses on the competitive advantages of the Hub and its value proposition in terms of strategic, operational, financial, talent and lifestyle aspects.

PharmaBoardroom provides industry trends, news and reports from all over the world. This site is for senior professionals who want to understand local and global markets.

CONTACT

Greater Geneva Bern area is an initiative of the cantons of
Bern, Fribourg, Vaud, Neuchâtel, Geneva and Valais.

World Trade Center – Av. de Gratta-Paille 2
PO Box 252
1000 Lausanne 22 – Switzerland

CONTACT

Copyright: All rights reserved. No part of this site maybe reproduced in any form or by any means, whether electronic, mechanical or otherwise including photocopying, recording or any information storage or retrieval system without prior written consent of PharmaBoardroom. While every attempt is made to ensure the accuracy of the information contained in this website, neither PharmaBoardroom nor the authors accept any liabilities for errors and omissions. Opinions expressed in this report are not necessarily those of the authors.

2021 © PharmaBoardroom